^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NP137

    i
    Other names: NP137, NP-137, NP 137
    Associations

    News

    Trials
    Company:
    NETRIS Pharma
    Drug class:
    Netrin -1 inhibitor
    Associations

    News

    Trials
    13d
    IMMUNONET: NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, Centre Leon Berard | Recruiting --> Active, not recruiting | N=87 --> 57
    Enrollment closed • Enrollment change
    |
    NP137
    13d
    Liver-NET1: Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC (clinicaltrials.gov)
    P1, N=43, Suspended, University Hospital, Grenoble | Recruiting --> Suspended
    Trial suspension
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • NP137
    17d
    LAP-NET1: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=43, Completed, University Hospital, Grenoble | Active, not recruiting --> Completed
    Trial completion
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    5-fluorouracil • oxaliplatin • irinotecan • NP137 • levoleucovorin calcium
    4ms
    Netrin-DCC Inhibition Suppresses Neuroendocrine Neoplasms Growth in vivo. (PubMed, Endocr Relat Cancer)
    We examined the effect of netrin on cell viability using DCC knockdown and NP137, a netrin-inhibiting antibody...TCGA analysis showed a negative correlation between NTN3 expression and survival. In conclusion, our data suggest that NTN-3, NTN-1, and DCC have interdependent oncogenic roles in PNENs, which can be reversed by blocking NTN binding to DCC.
    Preclinical • Journal
    |
    NTN1 (Netrin 1)
    |
    NP137
    9ms
    Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival. (PubMed, Nat Commun)
    In line with these data, a monoclonal netrin-1 blocking antibody (anti-netrin-1 mAb/NP137) has been preclinically developed and netrin-1 blockade has recently been investigated in phase 1 and 2 clinical trials in several adult cancers...In line with that, we next show that netrin-1 blockade potentiates the efficacy of SMO inhibitor therapy in vivo. Together, our data indicate that, netrin-1 blockade, used as monotherapy or in combination with SMO inhibitors, is a promising therapeutic strategy in SHH medulloblastomas.
    Journal
    |
    NTN1 (Netrin 1)
    |
    NP137
    10ms
    LAP-NET1: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=43, Active, not recruiting, University Hospital, Grenoble | Trial completion date: Mar 2027 --> Jun 2025 | Trial primary completion date: Mar 2026 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    5-fluorouracil • oxaliplatin • irinotecan • NP137 • levoleucovorin calcium
    1year
    AML-NET: Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] (clinicaltrials.gov)
    P1/2, N=1, Terminated, Centre Leon Berard | N=35 --> 1 | Trial completion date: Nov 2027 --> Feb 2025 | Recruiting --> Terminated | Trial primary completion date: Mar 2027 --> Feb 2025; low recruitment rate
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • NP137
    1year
    LAP-NET1: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=52, Active, not recruiting, University Hospital, Grenoble | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • NP137 • levoleucovorin calcium
    over1year
    GYNET: GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab (clinicaltrials.gov)
    P1/2, N=240, Active, not recruiting, NETRIS Pharma | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • NP137
    over1year
    LAP-NET1: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=52, Recruiting, University Hospital, Grenoble | Trial completion date: Nov 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Mar 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    5-fluorouracil • oxaliplatin • irinotecan • NP137 • levoleucovorin calcium
    over1year
    Liver-NET1: Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC (clinicaltrials.gov)
    P1, N=52, Recruiting, University Hospital, Grenoble | Trial completion date: Nov 2025 --> Mar 2027 | Trial primary completion date: Nov 2024 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • NP137
    over1year
    AML-NET: Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] (clinicaltrials.gov)
    P1/2, N=35, Recruiting, Centre Leon Berard | Initiation date: Dec 2023 --> Dec 2024
    Trial initiation date • Combination therapy
    |
    Venclexta (venetoclax) • azacitidine • NP137